The emergence of influenza A H7N9 in infection has posed a great threat to public health globally. Poor immunogenicity of H7N9 haemagglutinin (HA) is a major obstacle to the development of an effective H7N9 vaccine. Here, we found that the vaccine containing the H7HA head conjugated with IgG Fc (Hd-Fc) induced strong neutralizing antibody responses and protection against H7N9 infection, whilst the Fc-conjugated H7HA stalk (St-Fc)-based vaccine could not induce neutralizing antibodies, although the St-Fc-immunized mice were partially protected. The vaccines containing the full-length extracellular domain of HA conjugated with Fc and the mixture of Hd-Fc plus St-Fc induced significantly lower neutralizing antibody and haemagglutination inhibition titres than the Hd-Fc-based vaccine. These results suggest that the St-Fc may have inhibitory effects on the neutralizing immunogenicity of Hd-Fc. Therefore, the neutralizing domain(s), such as the receptor-binding domain, in the HA head should be kept and the non-neutralizing domain(s) in the HA stalk with the ability to potentially suppress the neutralizing immunogenicity of HA head should be removed from Fc-conjugated HA-based influenza vaccines to increase the neutralizing antibody response.
INTRODUCTION
As of 17 July 2015, 677 laboratory-confirmed cases of human H7N9 influenza virus, including 275 deaths in China, had been reported to the World Health Organization (WHO, 2015) . The emergence of family clusters of H7N9 infection indicates limited human-to-human transmission . In addition, one H7N9 virus isolated from humans was reported to be highly transmissible in ferrets by respiratory droplets , suggesting its pandemic potential. Vaccines are the most effective way to prevent morbidity, mortality and potential pandemics. As H7N9 is antigenically distinct from previous influenza vaccination contents, an effective H7N9 vaccine is urgently needed.
The clinical effects of several H7N9 vaccines have been reported. Results showed that 5.7 and 15.6 % of human participants receiving 15 and 45 mg haemagglutinin (HA) in virus-like particles after two vaccinations were seroconverted with haemagglutination inhibition (HI) titres w40, indicating that the H7N9 vaccine exhibited poor immunogenicity (Fries et al., 2013) . For a cell culture-derived MF59-adjuvanted H7N9 vaccine, 52 % and 78 % of human participants exhibited seroconversion in the HI and microneutralization assays, respectively (Bart et al., 2014) . Another MF59-adjuvanted H7N9 inactivated vaccine induced 59 % seroconversion in humans (Mulligan et al., 2014) . Therefore, compared with the efficacy of the 2009 H1N1 vaccine with a seroprotection rate upwards of 86.5 % after one dose of 7.5 mg non-adjuvant split-virion 2009 H1N1 vaccine, the currently tested efficacy of H7N9 vaccine is unsatisfactory (Liang et al., 2010) .
Influenza membrane protein HA is the most important antigen in influenza vaccine. The extracellular region of HA contains the HA head and the HA stalk (Steel et al., 2010) (Fig. 1) . The HA head binds to the influenza virus receptor sialic acid via its receptor-binding domain (RBD), whilst the HA stalk contributes to the fusion of the virus membrane and endosome membrane, thus introducing influenza genomes into the cell (Colman & Lawrence, 2003) . Previous reports have shown that the HA stalk may be developed as a universal influenza vaccine because of its relatively conserved sequence and ability to induce cellular immune responses and protection through antibody-dependent cell-mediated cytotoxicity (ADCC) effects (Bommakanti et al., 2010) . Our previous studies have demonstrated that conjugation of IgG Fc, which serves as an intramolecular adjuvant, to H5HA1 or its fragment significantly enhances the immunogenicity of the HA protein (Du et al., 2013c; Yu et al., 2015) , suggesting that Fc-conjugated HA protein or its subunit has the potential to be developed as an influenza vaccine.
In this study, we intended to design and develop H7N9 vaccine candidates based on the H7HA1 (head) and H7HA2 (stalk) conjugated with mouse IgG Fc. Surprisingly, we found that the Fc-conjugated H7HA head (Hd-Fc) induced strong neutralizing antibody responses. However, the Fc-conjugated H7HA stalk (St-Fc) did not elicit neutralizing antibodies, but might have suppressing effects on Hd-Fc's neutralizing immunogenicity, i.e. the ability of Hd-Fc to induce neutralizing antibody responses. Therefore, H7HA1 should be preferably selected for the design of a H7N9 vaccine based on the Fc-conjugated HA protein.
RESULTS

Design and expression of Fc-conjugated HA-based H7N9 vaccines
In order to make the design applicable to HA of various subtypes, we took advantage of the conserved disulfide bond formed by two cysteines in all influenza HAs. We located the two cysteines in H7N9 HA by aligning the H7HA amino acid sequence with that of HA from A/PR/8/34 and confirmed the result by the three-dimensional structure of H7HA (Fig. 1a) . Residues between the two cysteines were amplified by PCR, and the signal peptide of H7HA and the Fc fragment of mouse IgG were attached to the N terminus and C terminus, respectively, producing the secretory recombinant protein Hd-Fc.
Addition of Fc to the HA head and HA stalk is expected to facilitate purification and to enhance immunogenicity of the HA head and HA stalk, respectively, as the Fc fragment possesses a potent adjuvant effect (Qi et al., 2010; Du et al., 2013c; Yu et al., 2015) and can prolong the half-life of the linked immunogen (Zhang et al., 2009) . To construct St-Fc, we replaced the residues between the two cysteines in the extracellular domain of HA with four glycines as described previously (Steel et al., 2010) and added Fc to the C-terminal of the HA stalk. We then introduced two mutations, F402D and V412D, to stabilize the HA stalk in the neutral pH conformation as described previously (Bommakanti et al., 2010) . To construct HAe-Fc, we kept the mutations (F402D and V412D) and fused Fc to the C terminus of extracellular HA (Fig. 1b) . The recombinant genes were inserted into the pcDNA3.1 expression vector and transfected into 293T cells for expression. After purification with Protein G from the supernatant, the proteins were examined by SDS-PAGE and Western blot (Fig. 2) .
Fc-conjugated H7HA stalk-based vaccine did not induce neutralizing antibodies, but might have suppressing effects on the neutralizing immunogenicity of Fc-conjugated H7HA head
We immunized groups of mice (n55) twice at intervals of 3 weeks with 10 mg of each protein, including Hd-Fc, St-Fc, Hd-Fc+St-Fc and HAe-Fc. All vaccines were adjuvanted with MF59 to ensure that the difference between groups would not be based on dose-dependency. MF59 alone was used as control. H7HA-specific IgG titres were examined by ELISA. The differences of the H7HA-specific IgG titres amongst the groups were not significant (Fig. 3a) . We then tested the neutralizing antibody responses against pseudotyped H7N9 virus. The neutralizing antibody titre in sera of the Hd-Fc group was significantly higher than that of the St-Fc, HAe-Fc, Hd-Fc+St-Fc and control groups. Surprisingly, the sera from the St-Fc group could not neutralize H7N9 pseudovirus at the serum dilution of 1:20 (Fig. 3b) . Based on the order of neutralizing antibody titres in the four immunization groups, i.e. Hd-FcwHAe-FcwHd-Fc+St-FcwSt-Fc, and control, we concluded that the inclusion of the H7HA stalk in the vaccine would result in a decrease of neutralizing antibody titre. We then investigated whether the non-neutralizing antibodies induced by St-Fc could potentially suppress the neutralizing antibodies elicited by Hd-Fc, using normal mouse sera as a control. Sera from both the Hd-Fc and St-Fc groups, or control sera, were mixed at 1:1 for the H7N9 pseudovirus neutralizing assay. Results showed that antibodies induced by St-Fc had no significant influence on the titre of neutralizing antibodies elicited by Hd-Fc (Fig. 3c) , suggesting that the non-neutralizing anti-HA stalk antibodies do not inhibit the neutralizing activity of the anti-HA head antibodies. Subsequently, we used the HI assay to measure H7HA head-specific antibodies. We found that the sera of the Hd-Fc group exhibited the highest HI titres, about three-and fourfold higher than those in the sera of the HAe-Fc and Hd-Fc+St-Fc groups, respectively (Fig. 3d) . Similar to the pseudovirus neutralizing antibody response, the antisera in the St-Fc and control groups showed no detectable HI titre. These results further confirmed that the inclusion of H7HA stalk in an H7N9 vaccine may have suppressing effects on the neutralizing immunogenicity of the H7HA head, resulting in the decrease of neutralizing antibody titres in the sera of mice immunized with Hd-Fc+St-Fc or HAe-Fc.
Fc-conjugated HA head-based vaccine induced the best protection against H7N9 challenge
At week 4 post-second vaccination, all mice were challenged with 5 LD 50 influenza H7N9 virus. The survival rate in both the Hd-Fc and HAe-Fc groups was 100 %; however, the maximum body weight loss in the Hd-Fc group was 10 %, lower than the 14 % observed in the HAe-Fc group (Fig. 4) . The survival rate in the Hd-Fc+St-Fc group was 80 % with a maximum body weight loss of *20 %. The difference in body weight loss on days 3, 4 and 5 post-H7N9 challenge between the Hd-Fc and Hd-Fc+St-Fc groups was significant (Pv0.05), indicating that the combination of Fc-conjugated HA Fc-conjugated influenza A H7N9 vaccines head and stalk was worse than Hd-Fc alone in terms of inducing protection against H7N9. In the St-Fc group, the loss of body weight was severe; however, three of five mice managed to recover 5 days after H7N9 challenge so that the final survival rate was 60 %, whilst that of the MF59 control was 0 %. Overall, the protective effects in the Hd-Fc group were the best and consistent with the neutralizing antibody titres mentioned above.
DISCUSSION
Vaccination is an effective way to protect against infection from influenza virus and prepare for an influenza pandemic. However, in the case of H7N9, vaccines tested in the past have presented poor immunogenicity, even though adjuvants, such as MF59, could promote better immune responses, indicating the need for an improved vaccine. In this study, we found that vaccines based on Fc-conjugated H7HA head adjuvanted with MF59 were more effective than Fc-conjugated HA adjuvanted with MF59 and that Fc-conjugated H7HA stalk could, in fact, impede the neutralizing immune response to Fcconjugated HA head.
It was previously reported that co-administration of certain H5N1 antigens could offer better, or comparable, protection than HA alone; however, combining extra antigens can also be detrimental (Rao et al., 2010; Patel et al., 2012) . This might be explained by the overall poor immunogenicity of H5HA, which is not strong enough to compete for priority in the immune response. Under these circumstances, the inclusion of extra immunogens might not be a good option for improving H7N9 vaccines. Here, we report that even Fc-conjugated H7HA stalk, a component of H7HA, could be detrimental to the induction of neutralizing antibodies by Fc-conjugated H7HA head, another component of H7HA. Even though the immune response to Fc-conjugated H7HA stalk provided some protection against H7N9 challenge in mice, our results showed that the vaccine group based on Fc-conjugated H7HA head alone was more effective than the vaccine based on the Fc-conjugated H7HA extracellular region or the combination of Fc-conjugated H7HA head and stalk proteins.
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Antibodies elicited by Fc-conjugated H7HA stalk were not neutralizing; however, they did provide some protection against H7N9 challenge. Previous studies demonstrated that antibody against the HA2 subunit of H1HA was harmful by competing with neutralizing antibody (Khurana et al., 2013) . We show that antibodies induced by Fc-conjugated H7HA stalk were not competitive with the neutralizing antibody response elicited by Fc-conjugated H7HA head. However, part of the Fc-conjugated H7HA stalk-immunized mice were indeed protected, indicating that these non-neutralizing antibodies may protect the animals through another mechanism, such as the ADCC effect. The head sequences of HAs are variable amongst influenza virus strains, but the disulfide bond formed by two conformational adjacent cysteines is conserved. Therefore, the RBD containing critical neutralizing epitopes located in this loop region should be kept in the HA-Fc-based influenza vaccines. We have previously demonstrated that the Fc-conjugated RBD-containing H5N1 influenza vaccine induces strong cross-protection (Du et al., 2013c) . We have also shown that vaccines based on the RBD of spike proteins of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus elicit highly potent neutralizing antibody responses that protect animals from viral challenges (He et al., 2004; Du et al., 2007 Du et al., , 2008 Du et al., , 2009 Du et al., , 2013a Ma et al., 2014; Zhang et al., 2015) .
In summary, our results indicate that vaccines based on Fc-conjugated H7HA head are more effective than those based on Fc-conjugated H7HA stalk, which might, in fact, have suppressing effects on the neutralizing immunogenicity of Fc-conjugated HA head. From evidence obtained from this study, our approach may be applied to rationally design Fc-conjugated HA-based vaccines against other influenza viruses by keeping the neutralizing domain(s) and removing the fragments or epitopes that may reduce the neutralizing immunogenicity of the neutralizing domain, such as RBD.
METHODS
Construction, expression and purification of recombinant proteins. Genes encoding Hd-Fc, St-Fc and HAe-Fc were amplified by PCR with HA from A/Hangzhou/1/2013(H7N9) and Fc from mouse IgG, as shown in Fig. 1(a) . The recombinant genes were inserted into pcDNA3.1 expression vector and transfected into 293T cells for expression as described previously (Du et al., 2013b) . Culture medium was replaced by serum-free Dulbecco's modified Eagle's medium 10 h after transfection, and supernatant containing expressed proteins was collected 72 h post-transfection and purified by Protein G affinity chromatography.
Characterization of recombinant proteins by SDS-PAGE and
Western blot analysis. The purified proteins were first analysed by SDS-PAGE. Briefly, the proteins were boiled at 95 uC for 5 min and separated by 10 % Tricine gels, which were then stained with Coomassie blue. The purity of the purified proteins was w90 %. The proteins in the gel were transferred to nitrocellulose membranes for Western blot analysis. After blocking with 5 % non-fat milk in PBS/Tween 20 overnight at 4 uC, the blots were then incubated with HRP-conjugated goat anti-mouse IgG for 1 h at room temperature. Signals were visualized with enhanced chemiluminescence Western blot substrate reagents (Ma et al., 2014) .
Immunization and challenge studies. Female BALB/c mice were immunized twice intramuscularly with 10 mg Hd-Fc, 10 mg St-Fc, 10 mg Hd-Fc plus 10 mg St-Fc and 10 mg HAe-Fc, all adjuvanted with MF59 (5 % squalene, 0.5 % Tween 80 and 0.5 % Span 85 in citrate buffer, v/v) (Mastelic Gavillet et al., 2015) or MF59 alone as control, with an interval of 3 weeks for each group of five mice. Sera were collected at 3 weeks post-last vaccination to detect HA-specific IgG antibodies, neutralizing antibodies, HI titres and H7HA stalk-specific antibodies. At week 7, the anaesthetized mice were challenged intranasally with 5 LD 50 A/Shanghai/4664T/2013 (H7N9), and their survival and weight were monitored for 14 days. Mice that lost w25 % of their initial body weight were euthanized (Du et al., 2013c) . All experiments related to live H7N9 influenza viruses were performed in an approved Biosafety Level 3 laboratory at Fudan University in China.
ELISA. Collected mouse sera were analysed for specific antibody responses by ELISA (Du et al., 2008) . Briefly, 96-well ELISA plates were precoated with His-tagged HA protein of A/Hangzhou/1/2013 (H7N9) expressed in 293T cells overnight at 4 uC and blocked with 2 % non-fat milk for 2 h at 37 uC. Serially diluted mouse sera were added to the plates and incubated at 37 uC for 1 h, followed by four washes. Bound antibodies were incubated with HRP-conjugated goat anti-mouse IgG. The reaction was visualized by substrate 3,39,5,59-tetramethylbenzidine and stopped by 1 M H 2 SO 4 . A 450 was measured using an ELISA plate reader.
Pseudovirus neutralization assay. H7N9 pseudovirus was obtained through cotransfection with plasmids encoding Env-defective, luciferase-expressing HIV-1 genome (pNL4-3.luc.RE), pVKD-H7HA and pVKD-N9NA from A/Shanghai/4664T/2013 (H7N9) (Qiu et al., 2013) . Pseudovirus-containing supernatant harvested 72 h posttransfection was incubated with serially diluted mouse sera at 37 uC for 1 h before adding to confluent MDCK cells in 96-well cell culture plates after washing with PBS. After overnight incubation, the supernatant was replaced with DMEM. After 48 h, cells were lysed by cell lysis buffer (Promega) and transferred to 96-well luminometer plates. Luciferase substrate (Promega) was added, and relative luciferase activity was determined by an Ultra 384 luminometer (Tecan). The neutralization of HA pseudovirus was calculated and presented as 50 % neutralizing antibody titre (NT 50 ) (Du et al., 2010) .
HI assay. HI assays were performed according to the Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza (WHO, 2011). H7N9 pseudovirus was used as antigen. Mouse sera were treated with receptor-destroying enzyme at 37 uC for 18 h and inactivated by incubation at 56 uC for 30 min. Twofold diluted mouse sera (25 ml) were incubated with 4 HA units (25 ml) from H7N9 pseudovirus at 37 uC for 30 min and later 1 % guinea pig red blood cells (50 ml) were added. HI titre was defined as the highest dilution of the serum able to inhibit haemagglutination.
Statistical analysis. Statistical significance amongst different groups was calculated by Student's t-test. Pv0.05 was considered significant.
